摘要
The coronavirus disease 2019(COVID-19)threatens the health of humans worldwide,and at the time of this writing,there is no specifically targeted effective drug for COVID-19.The major initial symptoms of patients with COVID-19 are fever,dry cough,and fatigue,although some patients mainly experience vomiting,diarrhea,and other gastrointestinal symptoms.Other severe symptoms,namely chest tightness,dyspnea,and respiratory distress,usually appear one week later,with some patients rapidly developing acute respiratory distress syndrome(ARDS),septic shock,and possibly even death.A retrospective study of critically ill patients with COVID-19 has recently reported that 67.3%of patients presented with ARDS,28.9%with acute kidney injury,23.1%with heart injury,and 28.9%with abnormality in liver function.In addition,the 28-day mortality rate was up to 61.5%.[1]
基金
United Fund of National Natural Science Foundation of China(No.U2004110)
the Scientific and Technological Innovation Leaders in Central Plains(No.194200510017)
Provincial Ministry Co-construction Project from Medical Scientific and Technological Research Program of Henan Province of China(No.SBGJ2018020)
the"51282"Project Leaders of Scientific and Technological Innovative Talents from Health and Family Planning Commission in Henan Province of China(No.2016-32)
Zhengzhou City Science and Technology People-Benefit Project of Henan Province of China(No.2019KJHM0001)
Subject of Major National Science and Technology(No.2018ZX10101004)
Key Project of Novel Coronavirus Pneumonia Funded by Science and Technology Department of Hubei Province(No.2020FCA025)。
